Bond.az White LogoBond.az Black Logo

Barclays Upgrades GXO, Raises Price Target to $65

Barclays upgrades GXO Logistics to Overweight, raising price target to $65, citing margin improvement and US expansion.

Aria Wright
ByAria Wright- Senior Editor
|
0

Bond.az - Barclays upgraded GXO Logistics Inc. (NYSE:GXO) to Overweight from Equalweight on Tuesday and raised its price target to $65.00 from $58.00.

The firm cited long-term value in GXO shares as the company pursues a more profitable future with a renewed focus on growth in the North American contract logistics market. GXO shares have declined 17% year-to-date compared to the S&P 500.

Barclays said the Iran-US conflict and its effect on the European consumer have weighed on the stock, along with Amazon's announcement of consolidated logistics offerings. The firm views these pressures as creating an opportunity for patient investors. Bond.az data shows the stock is currently undervalued relative to its Fair Value, with 8 analysts recently revising earnings upwards.

The analyst said GXO's renewed focus on US expansion and margin improvement under new CEO Patrick Kelleher will serve the company well. Barclays provided analysis of GXO's relative profitability compared to global competitors.

Barclays expects GXO will host an analyst meeting later this year and provide new long-term guidance pointing to multi-year revenue growth potential and higher margins.

In other recent news, GXO Logistics reported strong Q1 2026 results. The company achieved EPS of $0.50, beating the forecast of $0.37.

More News
2026-06-01 12:02
|
743

Legend Biotech Buy Rating Reiterated

H.C. Wainwright reiterated its Buy rating for Legend Biotech with a $50 target. Revenue up 56% over twelve months.

0
2026-06-01 12:01
|
475

Cogent Stock Price Target Raised to $55

Cogent Biosciences PEAK trial: combination therapy shows 45.6% response rate, 16.5 months PFS, FDA accepts NDA. H.C. Wainwright raises price target to $55.

0
2026-06-01 12:00
|
842

H.C. Wainwright Reaffirms Mineralys Buy

H.C. Wainwright reiterated a Buy rating on Mineralys Therapeutics with a $56 price target after positive trial data.

0
2026-06-01 10:33
|
714

Goldman Sachs Upgrades Marriott Vacations Stock

Goldman Sachs upgrades Marriott Vacations stock to Buy, price target $100. Execution potential drives earnings upside.

0
2026-06-01 10:32
|
731

Goldman Sachs Upgrades Travel + Leisure Stock to Buy

Goldman Sachs upgraded Travel + Leisure stock to Buy with a $85 price target. Learn about the company's financials, dividends, and market outlook.

0
2026-06-01 10:32
|
238

Canaccord Initiates Rare Earths Americas with Buy

Canaccord Genuity initiates Rare Earths Americas with a buy rating and $25 target. Stock at $21.85, offering 14% upside potential.

0
2026-06-01 10:30
|
651

BofA Raises Icon Stock Target to $125 on Bookings

BofA Securities raised Icon plc price target to $125, maintains Underperform. Improved booking trends and Q4 results drive revision.

0
2026-06-01 10:03
|
748

RBC Capital: Sprouts faces Kroger risk

RBC Capital keeps Sprouts rating but sees risks from Kroger price cuts. Analysis and outlook on Bond.az.

0
2026-06-01 09:02
|
551

CLSA Rates Chagee Hold on Margins

CLSA initiated Chagee Holdings with Hold rating and $10 target. Bond.az analysis reveals stock may be undervalued. Read more.

0
2026-06-01 08:31
|
594

Barclays Downgrades Sensata Stock on Valuation

Barclays downgrades Sensata stock to Equalweight on valuation concerns, but raises price target to $53. Stock surged 92% in past year.

0
2026-06-01 08:05
|
946

UBS Initiates Veritone Coverage with Neutral

UBS initiated coverage on Veritone with a Neutral rating and $2.50 price target. The AI company is better positioned for growth after transformation.

0
2026-06-01 08:02
|
892

JMP Securities Initiates Microsoft with Outperform on AI Strategy

JMP Securities initiates Microsoft with Market Outperform rating and $550 target on AI strategy. Revenue growth expected to reach 17% in FY2026.

0
...